Tag: DAPT
Meta-analysis supports DAPT de-escalation after PCI
De-escalation to ticagrelor monotherapy does not increase ischaemic risk and reduces the risk of...
Effects of short DAPT “consistent regardless of high bleeding risk and complex PCI”
Research evaluating the effects of high bleeding risk (HBR) and complex percutaneous coronary interv...
ESC 2022: MASTER DAPT continues to show merit for shortened dual antiplatelet therapy out to 15 months post-PCI
Fifteen-month results from the MASTER DAPT trial have shown that the preserved ischaemic benefit...
ACC.22: TAVI patients treated with edoxaban see fewer incidences of leaflet thrombosis compared to DAPT
Patients treated with edoxaban for six months after a transcatheter aortic valve implantation (T...
ESC 2021: One-month dual antiplatelet therapy post-stent implant benefits high bleeding risk patients
One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk...
Panel explores the unanswered questions around short duration DAPT
Mounting evidence over the safety and efficacy of shorter-term dual antiplatelet therapy (DAPT) ...
Onyx ONE sub-analysis shows higher cardiac death for P2Y12 inhibitor compared to aspirin following DAPT
Azeem Latib (New York, USA) spoke to Cardiovascular News about a sub-analysis of the Onyx ONE st...
Resolute Onyx becomes first and only drug-eluting stent in Europe to have one-month DAPT indication for high bleeding risk patients
Medtronic has received the CE mark for a one-month dual antiplatelet therapy (DAPT) indication f...
CeloNova completes enrolment in first 14-day DAPT randomised controlled trial
CeloNova BioSciences has announced that it has successfully completed enrolment into the COBRA RED...
Enrolment completed for MASTER DAPT trial
A significant milestone has been reached for a landmark study into the use of short du...
GLOBAL LEADERS: no sex-difference in mortality or MI rates two years after PCI, but bleeding risk higher in women than men
A prespecified subgroup analysis of the GLOBAL LEADERS trial has found no between-sex difference...
Two further studies support three-month DAPT following PCI
Further evidence for a shorter duration of dual antiplatelet therapy (DAPT) in patients implante...
TCT 2019: Aspirin withdrawal after three months of dual antiplatelet therapy reduces bleeding without an increase in ischaemic events among high-risk patients following PCI
Data from the TWILIGHT study demonstrate that, compared to ticagrelor plus aspirin, ticagrelor m...
ACC 2019: Less bleeding with one-month DAPT than standard therapy, with no increased ischaemia
One-month dual antiplatelet therapy (DAPT) followed by 12 months of clopidogrel monotherapy leads to...
Patient recruitment reaches half-way point for global DAPT study
December marked a significant milestone for a major study into the use of short duration dual an...
Onyx One Clear study starts in USA and Japan
Medtronic has announced the start of the Onyx ONE Clear Study in the USA and Japan that will eva...
ESC 2018: Ticagrelor monotherapy approach does not challenge current DAPT approach
The GLOBAL LEADERS trial, simultaneously published in the Lancet and presented at the 2018 Europ...
ESC 2018: DAPT score “not generalisable” to a nationwide population
A new study has found that the dual antiplatelet therapy (DAPT) score, which is recommended by b...
Advantage of guided de-escalation of dual antiplatelet therapy seen in younger patients
A pre-specified analysis of the TROPICAl-ACS study indicates that de-escalating dual antiplatele...
ACC 2018: Short-term DAPT after PCI in acute coronary syndrome patients is not safe
Data from the SMART-DATE study indicate that acute coronary syndrome patients who receive short-...
First patient enrolled in trial reviewing 28-day DAPT with Xience
The first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet ...
ESC 2017: Case builds for dropping aspirin from triple therapy in atrial fibrillation patients post PCI
The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoa...
Medtronic to undertake global randomised clinical trial of one-month DAPT in Resolute Onyx patients
Medtronic has announced a global randomised clinical trial that will evaluate one-month dual ant...
EuroPCR 2017: Switching to clopidogrel after one month reduces bleeding without increasing ischaemic events
Data from the TOPIC (Timing of platelet inhibition after acute coronary syndrome) study indicate...
EuroPCR 2017: Greater risks with standard approach of dual antiplatelet therapy after TAVI
The ARTE study, which was simultaneously presented at EuroPCR (16–19 May, Paris, France) and pub...
Risk of bleeding with aspirin in patients older than 75 is higher than thought
Peter Rothwell (University of Oxford, Oxford, UK) and colleagues report in The Lancet that long-...
First patient enrolled in new study of abbreviated DAPT post-stent in high bleeding risk patients
Gillian Jessurun (Treant Zorggroep, Scheper Hospital Emmen, The Netherlands) has enrolled the first ...
ACC 2017: Dual anti-thrombotic approach has similar risk of bleeding to dual antiplatelet therapy
The GEMINI-ACS study, which was simultaneously presented at the 2017 scientific sessions of the ...
“Simple five-item risk score” could be used to predict bleeding risk associated with dual antiplatelet therapy
Francesco Costa (Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland) ...
Physicians may be overlooking patients’ desire to avoid dual antiplatelet therapy drawbacks
A study, published in Catheterization and Cardiovascular Interventions, found that most patients...
Procedural complexity should be considered when deciding duration of dual antiplatelet therapy
Gennaro Giustino and others report in the Journal of American College of Cardiology that—alongsi...
NICE recommends dual antiplatelet therapy with ticagrelor and aspirin
The National Institute of Health and Care Excellence (NICE) has published a final appraisal determin...
ESC 2016: Short-term DAPT is feasible with Nobori biodegradable polymer stent
The NIPPON (Nobori dual antiplatelet therapy as appropriate duration) study, presented in a hotline ...
